A. Gunkel

TL;DR: An externally validated model is developed to predict survival without tracheostomy and non-invasive ventilation for more than 23 h per day in European patients with ALS and could be applied to individualised patient management, counselling, and future trial design.

TL;DR: This study provides Class II evidence that elevated concentrations of CSF pNfH and NfL can accurately identify patients with ALS and shows an added value as diagnostic biomarkers for ALS, whereas the prognostic value of pNFH andNfL warrants further investigation.

TL;DR: There was no difference between groups in the primary outcome of survival, although post-hoc analysis suggested that rasagiline might modify disease progression in patients with an initial slope of Amyotrophic Lateral Sclerosis Functional Rating Scale Revised greater than 0·5 points per month at baseline.

TL;DR: In patients not reporting dyspnoea and having an FVC of >75%, nocturnal hypoventilation was observed in nearly every second patient, suggesting polygraphy does not provide useful additional information if the FVC is already <75% as predicted, but in patients with more or less normal lung function parameters or where lung spirometry cannot perform adequately, it can provide sufficient evidence for the need of NPPV.

TL;DR: The results confirm the hypothesis that Ca(2+) abnormalities in ALS are measurable in immune cells and suggest that the reduction of P2X7 receptor expression on PBMCs leads to intracellular calcium dysregulation.